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Abstract
Background: Little is known about the prevalence of HIV or HCV in injecting drug users (IDUs)
in Serbia and Montenegro. We measured prevalence of antibodies to HIV (anti-HIV) and hepatitis
C virus (anti-HCV), and risk factors for anti-HCV, in community-recruited IDUs in Belgrade and
Podgorica, and determined the performance of a parallel rapid HIV testing algorithm.
Methods: Respondent driven sampling and audio-computer assisted survey interviewing (ACASI)
methods were employed. Dried blood spots were collected for unlinked anonymous antibody
testing. Belgrade IDUs were offered voluntary confidential rapid HIV testing using a parallel testing
algorithm, the performance of which was compared with standard laboratory tests. Predictors of
anti-HCV positivity and the diagnostic accuracy of the rapid HIV test algorithm were calculated.
Results: Overall population prevalence of anti-HIV and anti-HCV in IDUs were 3% and 63%
respectively in Belgrade (n = 433) and 0% and 22% in Podgorica (n = 328). Around a quarter of
IDUs in each city had injected with used needles and syringes in the last four weeks. In both cities
anti-HCV positivity was associated with increasing number of years injecting (eg Belgrade adjusted
odds ratio (AOR) 5.6 (95% CI 3.2–9.7) and Podgorica AOR 2.5 (1.3–5.1) for ≥ 10 years v 0–4
years), daily injecting (Belgrade AOR 1.6 (1.0–2.7), Podgorica AOR 2.1 (1.3–5.1)), and having ever
shared used needles/syringes (Belgrade AOR 2.3 (1.0–5.4), Podgorica AOR 1.9 (1.4–2.6)). Half
(47%) of Belgrade participants accepted rapid HIV testing, and there was complete concordance
between rapid test results and subsequent confirmatory laboratory tests (sensitivity 100% (95%CI
59%–100%), specificity 100% (95%CI 98%–100%)).
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Conclusion: The combination of community recruitment, ACASI, rapid testing and a linked
diagnostic accuracy study provide enhanced methods for conducting blood borne virus sero-
prevalence studies in IDUs. The relatively high uptake of rapid testing suggests that introducing this
method in community settings could increase the number of people tested in high risk populations.
The high prevalence of HCV and relatively high prevalence of injecting risk behaviour indicate that
further HIV transmission is likely in IDUs in both cities. Urgent scale up of HIV prevention
interventions is needed.
Background
While an evidence base characterising the epidemiology
of HIV and hepatitis C virus (HCV) among injecting drug
users (IDUs) has emerged in many Eastern Europe coun-
tries,[1,2] less is known of South Eastern European coun-
tries, including the Western Balkans. This is despite
countries in the Western Balkans and Eastern Europe shar-
ing many characteristics of the HIV risk environment,
such as major social and economic transition linking with
expanding illicit drug markets, increased poverty, and
weakening public health infrastructure.[3] Studies suggest
low prevalence of HIV in IDUs in the region but higher
prevalence of HCV, with estimates ≥ 50% in Bulgaria,
Romania, Slovenia and Croatia.[4] There are only two
published surveys of HIV prevalence among IDUs in Ser-
bia,[5,6] and none in Montenegro. In Belgrade, HIV prev-
alence was 39% in 472 IDUs admitted to a drug treatment
centre in 1987/8.[5] A later study of IDUs treated for drug
problems in Belgrade found that 44% were anti-HIV pos-
itive.[6] HIV and AIDS registry data suggest that injecting
drug use is yet to be a major transmission route for HIV in
Serbia and Montenegro; between 2002 and 2006, 494
newly diagnosed HIV infections were reported in Serbia,
of which 66 were attributed to injecting drug use, and sim-
ilarly 25 in Montenegro, of which 3 were in IDUs.[7] No
estimates of anti-HCV prevalence in IDUs in Serbia and
Montenegro have been published.
A number of contextual factors shape the delivery of HIV
and HCV testing services for IDUs in Serbia and Montene-
gro, which in turn introduce challenges for conducting
sero-epidemiological research.[8,9] Resources for the
delivery of low-threshold and confidential HIV and HCV
antibody testing at testing centres is limited, with reports
of inconsistent availability of testing kits. Qualitative
research suggests reluctance among IDUs to access local
testing centres, related to concerns over confidentiality, a
lack of trust in services and expertise, and experience of
stigma when interfacing with health care and other insti-
tutions.[8,9] Avoidance of service contact can be a strategy
of stigma avoidance.[8] There exists a culture of silence
and non-disclosure regarding viral infections among
some sectors of the IDU population.[8] This emphasizes
the need for sero-epidemiological research approaches
which focus upon methods of community recruitment. It
also emphasizes the potential afforded by delivering HIV
and other testing services directly in the community and
outside the laboratory. At the time of the study, however,
all HIV and HCV testing services in Serbia and Montene-
gro were provided within designated medical centres. This
study obtained specific approval by the relevant Govern-
ment Ministries to offer point-of-care tests (POCT) for
HIV directly in community settings as part of its aim to
explore improvements in survey methods in sero-epide-
miological research in hidden populations of IDUs.
Sampling hidden populations
Although most epidemiological studies measuring HIV
and HCV prevalence in IDUs recruit a theoretically biased
selection of participants from drug treatment clinics, some
have used "snowball sampling", often with peer inter-
viewers, to recruit IDUs from non-treatment community
settings. These "community based" snowball samples are
often themselves biased by several factors, including over-
sampling of participants with larger social networks,
insufficient recruitment waves rendering a final sample
with characteristics biased by the initial participants, and
widespread masking (protecting friends due to privacy
concerns) and volunteerism.[10,11] Recently, a modified
version of snowball sampling, known as "respondent
driven sampling" (RDS), has been developed which aims
to eliminate several such biases to achieve representative
samples of high risk, hard-to-react populations.[10,12]
RDS uses a coupon system of recruitment whereby peers
recruit their peers to create numerous recruitment waves,
long recruitment chains and an incentive mechanism for
participating in the study; this in turn helps eliminate
some of the biases inherent in snowball sampling meth-
ods.[10,13] Furthermore, data gathered using RDS are
subject to specialised statistical analysis to mitigate factors
associated with biased recruitment.[13,14] However, the
method has been associated with operational, design and
analytical challenges in some studies [15] and there is
some discussion about the ethics of incentive-based
recruitment systems [16]. RDS requires careful implemen-
tation to maximise its success.
Services at the point of recruitment
RDS studies usually have fixed locations where partici-
pants redeem their coupons and enrol in the survey. This
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offers researchers the opportunity to provide much
needed services to these populations, as well as improve
the validity and reliability of survey methods. For
instance, many previous studies have employed unlinked
anonymous testing of biological samples in which, for
practical reasons, results are not returned to participants:
turnaround times for returning results from a reference
laboratory are usually in the order of days rather than
hours; re-contacting marginalised groups to deliver test
results are poor.[17] Point-of-care tests (POCT) for HIV
offer a novel and alternative strategy whereby the testing
is moved from the laboratory into the community, in this
case to the RDS study site, and results can be provided to
the most hard-to-reach populations at the same visit.[18]
POCTs are simple to use and thus facilitate administration
by non-laboratory staff who have received appropriate
training and had their competency checked. This enables
voluntary counselling and testing (VCT) programmes to
be extended to community settings and offered as an
added incentive to participate in epidemiological studies.
Fixed sites also enable studies to use audio-computer
assisted survey interviewing (ACASI), which has been
shown to elicit higher reports of high risk and often stig-
matised behaviours, which are assumed to be closer to
true levels.[19,20]
Recent studies suggest that rapid HIV testing in commu-
nity settings can effectively target groups at high risk of
HIV infection.[21] Rapid testing has been conducted in
parks, shelters, syringe exchanges, community clinics,
VCT programmes and antenatal clinics. [21-25] The per-
formance of algorithms employing several different
POCTs either in consecutive or parallel testing strategies
has also been reported, with varying outcomes. One field
evaluation suggested that different combinations of
POCTs provided sensitivity and specificity similar to
standard enzyme immunoassays and Western Blot.[22]
Another study evaluating the performance of the Deter-
mine HIV-1/2 in pregnant women in Mexico reported
high sensitivity and specificity, though a lower positive
predictive value associated with the low prevalence of
anti-HIV in this population.[25] Another study reported
successful implementation of rapid HIV testing in several
different types of community settings but only measured
the positive predictive value for those receiving confirma-
tory tests after testing anti-HIV positive on the rapid HIV
assay.[21] A study employing the Determine and Uni-
Gold rapid HIV test assays in Uganda reported good sen-
sitivity, though specificity was compromised because of
the occurrence of weak reactions with the test band. These
weak reactions were associated in the main with the
Determine test, most of which were later ascertained to be
HIV negative on enzyme immunoassay (EIA) and Western
blotting.[26]
This paper reports on the findings of two parallel surveys
of IDUs conducted in Belgrade and Podgorica in 2005
using RDS. Both recruited IDUs from community settings
and employed ACASI, with the Belgrade survey including
a voluntary confidential rapid HIV testing component and
a diagnostic accuracy study.
Methods
Two cross sectional, anonymous, surveys of IDUs were
undertaken simultaneously in Belgrade and Podgorica in
September and October 2005. Both surveys used identical
sampling and interview methods. Inclusion criteria were:
injecting drugs in the previous four weeks; living or work-
ing in Belgrade or Podgorica; aged 18 years or older; will-
ing to give a dried blood spot (DBS) for antibody testing;
and not having been interviewed for the study previously.
Participants were recruited using RDS,[10] and were inter-
viewed at fixed sites located in the centre of each city. The
Belgrade site was housed within a discrete building used
by the International AID Network (IAN), an NGO work-
ing with vulnerable people in South Eastern Europe. The
Podgorica site was housed within some unmarked rooms
in a mini shopping mall near the centre of the city, and
comprised part of the premises of a local NGO called
"Juventas", which provides youth services in the city. Sur-
vey staff members in both cities included outreach work-
ers and former injectors whom had extensive experience
working with vulnerable populations in Serbia and Mon-
tenegro. Potential participants were screened using a list
of questions about injecting drug preparation, type and
cost and by looking at injection stigmata. Pre-survey train-
ing in both cities included RDS methodology, processing
potential participants through screening for inclusion cri-
teria, gathering RDS specific data for analysis, providing
assistance to participants using ACASI, and managing
incentive payments. Recruitment began with a set of ini-
tial recruits ("seeds") who met the inclusion criteria and
who were diverse in terms of key characteristics of the
drug injecting community (eg. age, gender, area of resi-
dence, duration of injecting).
After giving written informed consent, all participants
were interviewed using ACASI, taking approximately 30
minutes to complete. The questionnaire included sections
on socio-demographics, drug use, injecting and sexual risk
behaviour, sex work, contact with the police, and HIV test-
ing history. It was developed from other survey question-
naires[2,27], underwent piloting, and was informed by a
linked qualitative study.[9]
Upon completion of the ACASI, all participants gave at
least two DBS specimens for unlinked anonymous testing
for anti-HIV and anti-HCV. Participants were given spe-
cific information detailing the unlinked anonymous
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nature of DBS testing in the Information Sheet for the
study, and had the option to withdraw consent and opt
out of the study. No identifiers were collected and so it
was not possible to trace participants to report to them
their test results. However all participants in Belgrade were
offered voluntary anonymous rapid HIV testing and
results, along with full pre- and post-test counselling. HIV
test results were available within approximately 30 min-
utes after receiving pre-test counselling. Those testing HIV
positive were referred to the Belgrade AIDS centre for
appropriate confirmatory testing. HIV/AIDS educational
materials, condoms and trained VCT counsellors were
available throughout the duration of the study. In Podgor-
ica, instead of rapid testing, participants were referred to a
local, newly opened, free of charge HIV VCT centre.
IDUs received "primary" and "secondary" cash reimburse-
ments of €10 each for participation in the survey and €5
for each of their recruited peers (maximum three) who
met the inclusion criteria and enrolled in the survey.
Laboratory methods – unlinked anonymous testing
Capillary blood was collected onto absorbent paper
(Whatman 903, Astron, Huntingdon, UK) by finger prick
using single use disposable lancets, and left to dry, thus
becoming a DBS. Specimens were stored in plastic
pouches with desiccant in on-site freezers, and were later
transferred to the Clinic for Infectious and Tropical Dis-
eases, Belgrade where they were stored at -25°C until test-
ing.
DBS specimens were tested at the Clinic for Infectious and
Tropical Diseases, Belgrade, under the supervision of staff
of the Health Protection Agency Virus Reference Depart-
ment. Six mm diameter disks were punched and each was
placed in a designated well of a 96-well microplate.
Plasma proteins, including antibodies, were eluted from
the disks by overnight immersion in 200 μL of PBS/tween
buffer.
Anti-HCV test
Testing for anti-HCV was carried out using a modified
protocol for the Ortho HCV 3.0 SAVe ELISA (product
number 940982, Ortho Diagnostics, Amersham).[28] The
method employs a cut-off (CO) optical density (OD) of
0.090, and any DBS sample giving an OD value between
0.080 and 2.500 was re-eluted from a new punch and re-
tested in duplicate using the same assay. Those that were
repeatedly reactive, as well as those whose initial screen-
ing OD value exceeded the maximum for the plate reader
(2.500), were considered to be anti-HCV positive. It was
decided not to apply a second line assay with the intent to
confirm the presence of anti-HCV primarily because the
method employed is highly reproducible and specific.
Even for a low HCV prevalence in IDUs of, for example,
30% the positive predictive value is 1.0.[28] Particularly
with the added safeguard of duplicate re-testing of any
specimen with an OD in the range 0.08 – 2.5 the applica-
tion of a second test would not have added significantly to
testing accuracy.
Anti-HIV test
For Anti-HIV testing an in-house version of the Abbott/
Murex GACELISA HIV 1+2 enzyme immunoassay was
employed.[29] The commercial GACELISA HIV 1+2 test
was established in several studies to provide sensitivity
and specificity close to 100% [30] and good sensitivity
shortly after anti-HIV seroconversion.[31] Development
of the commercial kit was led by one of the authors (JVP),
but ceased to be manufactured in 2003. Consequently, an
in-house version of the GACELISA was developed and val-
idated at the HPA Centre for Infections. In brief, the assay
employs a 96-well U-bottomed microplate solid phase
(Nunc Maxisorp) coated with anti-human IgG antibodies
(A0423, Dako UK Ltd), negative and positive controls
(HIV-1 × 2 and HIV-2 × 1), specimen diluent (PBS with
10% fœtal bovine serum and 0.1% tween 20), each pre-
pared in bulk at HPA, along with the conjugate (HRPO-
tagged HIV-1 and HIV-2 antigens) and substrate (TMB),
with their associated buffers scavenged from the Abbott/
Murex HIV-1.2.0 GE95 EIA kit. The test is processed
employing standard EIA equipment and absorbances are
measured at 450 nm employing 630 nm as a reference.
The cut-off is calculated as the mean OD of 4 negative
controls + 0.2, and performance limits are applied that
were established when the assay was developed and form
part of routine QC monitoring. Validation of the assay
was performed employing a panel of oral fluid specimens
whose HIV status had been determined employing oral
fluid specimens first characterised with the commercial
Abbott Murex Diagnostics' GACELISA HIV 1+2 EIA
(VK61). The validation panel comprised 194 anti-HIV-1
positive oral fluid specimens collected in the course of
surveillance activities during 2001–2002 and 653 anti-
HIV negative specimens collected during 2001 and 2003.
The in-house GACELISA method detected 191/194 anti-
HIV positive specimens, equivalent to a sensitivity of
99.5% (95% CI 96.7–100%). The falsely negative speci-
men was retested and found to be weakly reactive (OD/
CO 1.21). Of 654 anti-HIV negative specimens all but 3
were non-reactive, a specificity of 99.5% (95% CI 98.5–
99.9%). While all anti-HIV positive specimens were, by
definition, detected by the commercial VK61 GACELISA
HIV 1+2 EIA, it generated 7 false positive reactions, a spe-
cificity of 98.9% (95% CI 97.7–99.5%). Specimens that
were anti-HIV reactive on initial testing were re-tested
using the GACELISA. All repeatedly reactive samples and
several of those that were reactive only on initial testing
were examined by a modified Western Blot procedure
(HIV Blot 2.2, Abbott Diagnostics, Maidenhead, UK).
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For Anti-HIV testing an in-house version of the GACELISA
HIV 1+2 enzyme immunoassay was employed [29] as the
commercial kit is no longer manufactured. In local valida-
tion studies it had been shown to have an accuracy equiv-
alent to that of the commercial GACELISA. Specimens
that were anti-HIV reactive on initial testing were re-tested
using the GACELISA. All repeatedly reactive samples and
several of those that were reactive only on initial testing
were examined by a modified Western Blot procedure
(HIV Blot 2.2, Abbott Diagnostics, Maidenhead, UK).
Rapid HIV testing
Rapid HIV testing was conducted using a parallel rapid
testing algorithm. Capillary blood samples collected using
single use disposable lancets were dropped into the sam-
ple ports of the rapid test devices according to the manu-
facturers' instructions. An additional DBS was taken from
each participant for anti-HIV confirmatory testing (proto-
col as above) at a later date to estimate the diagnostic
accuracy of the algorithm.
Two rapid HIV tests, Uni-Gold Recombinant HIV-1/2
(Trinity Biotech, Bray, Ireland) and Determine HIV-1/2/O
(Abbott Laboratories, Abbott Park, IL, USA) were
employed simultaneously to avoid the need to take a sec-
ond blood sample should the first test be reactive. These
tests have undergone evaluation by the World Health
Organization; both had 100% sensitivity, with the Deter-
mine test having 99.4% and Uni-Gold 100% specifi-
city.[32] A detailed protocol was followed which
incorporated the manufacturers' instructions for use. Test-
ing was conducted in a small temporary laboratory estab-
lished within the Belgrade study site, and each test result
was read by two trained technicians.
Additional file 1 describes the rapid testing algorithm.
Reactivity of at least one rapid test result (two red bars,
one in the "Test" and one in the "Control" window) indi-
cated the possibility of HIV infection and the participant
was referred to the Belgrade AIDS centre for appropriate
confirmatory testing. Blood samples that were concord-
antly non-reactive, or where one test was non-reactive and
the other invalid, were interpreted as indicating no evi-
dence of HIV infection, and in which case no referral was
made. In addition, the intensity of each reaction was
recorded on a scale of one to four (no reaction; weak reac-
tion; moderate reaction; strong reaction), as a quality
check.
Statistical analysis
Characteristics of the two samples of IDUs were com-
pared, and the Respondent Driven Sampling Analysis
Tool (RDSAT) v. 5.0.1 http://www.respondentdrivensam
pling.org was used to weight the sample to control for dif-
ferences in network size, homophily (the tendency for
people to preferentially recruit others similar to them-
selves) and recruitment patterns, to provide population
based estimates and 95% confidence intervals (CI) of IDU
characteristics in each city.[33] Correct implementation of
RDS methodology (eg collection of participant's network
sizes, and tracking who recruited whom) and analysis
with RDSAT, provides representative estimates of the pop-
ulation sampled.[14]
We then evaluated predictors of anti-HCV positivity using
univariable and multivariable logistic regression, consid-
ering the following variables: age group, sex and educa-
tion; injecting drug use characteristics (duration of
injecting, frequency of injecting, main drug injected, fre-
quency of use of new needles/syringes, main source of
new needles/syringes); injecting risk behaviours and ever
having engaged in sex work; history of arrest, imprison-
ment, drug treatment and HCV testing. As a result of
incorrect programming of ACASI, which allowed some
questions to be skipped without a value being entered,
several variables had ≥ 5% missing values: duration of
injection (20%); frequency of injection (9%); main drug
injected (9%); number of times using a needle/syringe
before disposal (21%); main source of new needles/
syringes (9%); ever injected with used needles/syringes
(12%); injected with used needles/syringes in the last four
weeks (19%); shared injecting paraphernalia (9%); ever
engaged in sex work (16%); and ever detained or arrested
by the police (36%). Therefore multiple imputations were
used in multivariable models assuming the data were
missing at random to avoid excluding different injectors
from different analyses.[34] This involved creating or
imputing plausible values for missing observations
reflecting the uncertainty about the non-response model.
Fifteen imputations were run on the missing data. The
imputed datasets were combined and analysed together to
allow for the uncertainty in the imputation model to be
taken into account. Multivariable models were adjusted
for robust standard errors as there was evidence of cluster-
ing by recruitment network. Statistical significance was
assessed using Wald tests. All analyses were conducted
using Stata 10 (Stata Corp, College Station, Texas).
Multivariable models were also adjusted for population
weights on key demographic indicators to compensate for
recruitment biases. Population weights adjusting for
recruitment biases by education and sex were used for Bel-
grade, and age and education for Podgorica. Population
weights were calculated using RDSAT v. 5.0.1 with anti-
HCV status as the outcome variable.
Ethics
Ethics approval was granted in the United Kingdom by the
Charing Cross Research Ethics Committee. In Belgrade,
the Ethics Committee of the Medical Faculty at the Uni-
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versity of Belgrade approved the study and, in the absence
of a suitable research ethics committee in Podgorica,
approval for the study was granted by the Montenegrin
Ministry of Health. In addition the Serbian Ministry of
Health granted specific approval for the collection of bio-
logical specimens at study sites, and the rapid testing algo-
rithm.
Results
Sample and population characteristics
Additional file 2 shows both sample and population char-
acteristics of IDUs recruited in Belgrade (n = 433) and
Podgorica (n = 328). After adjusting for differences in net-
work sizes, homophily and recruitment patterns, most
population estimates of most characteristics were similar
to observed proportions in both cities. However, in Bel-
grade sample characteristics underestimated by ≥ 10% the
proportion of IDUs in the population who had injected
less than daily (47% observed v 59% population) and
used a pharmacy for their main source of needles/syringes
(72% v 83% respectively).
A quarter of the sample (27%) in Belgrade, and 41% in
Podgorica, were aged <25 years; 22% and 7% respectively
were female; 26% and 16% respectively reported having
been in higher education (≥ 12 years schooling). A higher
percentage of IDUs in Podgorica had shorter injecting
careers (68% v 34% ≤ 4 years, respectively), obtained their
syringes from an "other" source (29% v 1%), and had ever
injected with used needles/syringes (66% v 50%) than
those in Belgrade. Levels of other injecting and sexual risk
behaviours were similar in both samples. Around a quar-
ter in each city had injected with used needles and
syringes in the last four weeks, and around 5% had ever
engaged in sex work. A higher proportion of Belgrade
injectors had been detained or arrested by the police in
the last 12 months (62% v 52% respectively), imprisoned
(43% v 34%), previously been in drug treatment (45% v
28%), and had ever been tested for HCV (51% v 24%).
Laboratory testing for anti-HIV and anti-HCV
DBS from the IDUs recruited in Belgrade and Podgorica
were tested for anti-HIV and anti-HCV. Fifteen were ini-
tially reactive by GACELISA HIV 1+2, and there was excel-
lent discrimination between non-reactive and reactive
specimens (Figure 1). All 15 were repeatedly reactive (all
OD/CO > 8.0), and all were confirmed to contain anti-
HIV-1 by Western blot. A further seven specimens were
initially weakly reactive (OD/CO 1.02–2.08), of which six
were non-reactive on re-testing. As a quality check, three
of these six were examined by Western Blot and were non-
reactive. The remaining specimen (initial OD/CO 2.01)
was not re-tested by GACELISA or Western blot and was
therefore excluded from further analyses. Of the 315 DBS
specimens tested in the diagnostic accuracy study 11 were
initially reactive, ten of which were confirmed by Western
blot to be anti-HIV-1 positive.
The anti-HCV reactivities also showed excellent polarisa-
tion between those non-reactive and those that were reac-
tive (Figure 2). To check for reproducibility, 55 samples
that gave an OD in the range 0.8–2.5 were retested in
duplicate. All of those with an OD/CO > 1.0 were repeat-
edly reactive, apart from a single DBS whose initial OD/
CO was weak, at 2.2 (retest OD/CO 0.03). The two sam-
ples with an initial OD/CO between 0.8 and 1.0 were
non-reactive on repeat testing. The anti-HCV test method
employed also exhibited very good quantitative reproduc-
ibility. Figure 3A illustrates the close correlation between
the initial anti-HCV reactivity and the mean of the dupli-
cate re-tests (R2 = 0.92), and figure 3B that between the
duplicate re-tests (R2 = 0.99).
GACELISA HIV 1+2 distribution of initial OD/CO values (n = 757)Figure 1
GACELISA HIV 1+2 distribution of initial OD/CO 
values (n = 757).
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Anti-HCV testing distribution of initial OD/CO values (n = 748)Figure 2
Anti-HCV testing distribution of initial OD/CO val-
ues (n = 748).
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Overall adjusted population estimates of bloodborne
virus prevalence were 3% (CI 2–6%) for anti-HIV and
63% (CI 57–70%) for anti-HCV for IDUs in Belgrade, and
0% (CI 0–1%) and 22% (CI 17–27%) for IDUs in
Podgorica.
Predictors of anti-HCV positivity
Additional file 3 displays univariable and multivariable
predictors of anti-HCV positivity. Predictors of anti-HIV
positivity were not explored as anti-HIV prevalence was
too low. In Belgrade, females were more likely to be
infected with HCV than males (adjusted odds ratio (AOR)
2.3, CI 1.5–3.7), and prevalence was lower in those with
secondary or higher education compared to only primary
(AOR 0.4, CI 0.2–0.8 and AOR 0.2, CI 0.1–0.6 respec-
tively). Prevalence and odds also increased with length of
injecting (eg. AOR 5.6, CI 3.2–9.7 for ≥ 10 years v 0–4
years), and were higher for those who injected daily com-
pared to less than daily (AOR 1.6, CI 1.0–2.7). Those who
used a needle or syringe two or more times prior to dis-
posal had half the odds of anti-HCV compared to those
using it just once (AOR 0.5, CI 0.3–0.7), whilst partici-
pants reporting having ever injected with used needles
and syringes had twice the odds than those who had not
(AOR 2.3, CI 1.0–5.4). Finally, for Belgrade anti-HCV
prevalence was higher in those who had ever been in
prison (AOR 1.6, CI 1.1–2.5).
In Podgorica, as in Belgrade, anti-HCV positivity was asso-
ciated with longer lengths of injecting, albeit less mark-
edly (AOR 2.5, CI 1.3–5.1 for ≥ 10 years v 0–4 years), as
well as daily injecting (AOR 2.1, CI 1.3–5.1) and ever hav-
ing injected with used needles and syringes (AOR 1.9, CI
1.4–2.6) (Additional file 3). In contrast to Belgrade, anti-
HCV positivity in Podgorica was also raised in older par-
ticipants (AOR 3.5, CI 2.2–5.8 for those aged ≥ 30 v <25
years), those who had been detained or arrested by the
police in the last 12 months (AOR 2.5, CI 1.2–5.2) and
those ever tested for HCV (AOR 2.0, CI 1.4–2.9).
There were minor differences in predictors of anti-HCV
positivity in the multivariable imputed models displayed
in Additional file 3 and ordinary multivariable models
(not shown). For Belgrade, frequency of injection was
associated with anti-HCV in the imputed but not the ordi-
nary model (OR = 1.3, CI 0.8–2.21), as was ever injected
with used needles/syringes (OR = 2.5, CI 0.9–7.1). For
Podgorica higher education was associated with anti-HCV
positivity in the ordinary model (OR = 6.9 CI 3.1–15.1)
but not the imputed model, as was ever sex work (OR =
2.2, CI 1.0–4.5) and ever received drug treatment (OR =
3.3, CI 2.0–5.5 for current treatment).
Rapid testing uptake and diagnostic accuracy
All participants in Belgrade were offered a rapid HIV test,
of whom 204 (47%, CI 42%–52%) took up the offer. Five
withdrew after pre-test counselling, resulting in 199 par-
ticipants with rapid test results. For these, an additional
DBS was collected from 176 participants for confirmatory
testing.
Additional file 4 shows a comparison of the results from
the rapid test algorithm and the confirmatory testing.
There was complete concordance between the rapid test
algorithm and confirmatory tests, resulting in excellent
specificity and negative predictive value (100.0%, CI
97.8–100.0% for both indicators), as well as sensitivity
and positive predictive value (100%, CI 59.0–100.0% for
both indicators) albeit with a wide confidence interval
reflecting the small number of true positives in the sam-
ple.
The intensity of reaction for all 191 negative results on the
Unigold test was recorded as "0" (no reaction; for one par-
ticipant the Determine test alone was employed). For the
seven positive reactions, one scored "2" (moderate reac-
A: Comparison of anti-HCV initial screen & mean re-test OD/CO valuesFigure 3
A: Comparison of anti-HCV initial screen & mean re-
test OD/CO values. A new disc was punched eluted and 
tested in duplicate when the initial eluate gave an OD in the 
range 0.080 – 2.500 (n = 53). B: Comparison of duplicate 
anti-HCV OD/CO values on new eluates from DBS whose 
initial screen OD was in the range 0.080 – 2.500 (n = 53).
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tion) and six scored "3" (strong reaction). Similarly for the
Determine, all 192 negative results scored "0", whilst all
seven positive reactions scored "3".
Discussion
A simple analysis of the laboratory findings indicated how
well the test protocols developed for anti-HIV and anti-
HCV testing of DBS segregate reactive and non-reactive
specimens. Moreover, retesting the anti-HIV reactive spec-
imens and confirmatory testing with Western blot high-
lighted the specificity of the GACELISA method. Similarly,
retesting the minority of anti-HCV specimens whose reac-
tivity was not at the extremes of the distribution of reactiv-
ities demonstrated the reproducibility of the method. Our
original description of the anti-HCV DBS method indi-
cated that it was highly accurate and these findings are
consistent with that conclusion.[28]
Prevalence and risk
In our study, prevalence of anti-HIV was 3% in Belgrade
and 0% in Podgorica, suggesting that injecting drug use is
yet to have a major impact on the HIV epidemic in either
city. However, the much higher prevalence of anti-HCV, at
around 60% for Belgrade and 20% for Podgorica, and
high levels of injecting risk behaviour, indicate the need
for a cautious response as levels of risk behaviour appear
sufficient to enable considerable onward bloodborne
virus transmission. Our study indicates that only half of
IDUs in Belgrade and only a quarter of IDUs in Podgorica
had ever been tested for HCV, and around a quarter of
IDUs in both cities reported injecting with used needles
and syringes in the previous four weeks.
IDUs in Podgorica were younger, had shorter duration of
injecting, and were less likely to inject on a daily basis
than their Belgrade counterparts, suggesting a more recent
introduction of injecting drug use in Podgorica. Three risk
factors for anti-HCV were the same for the two cities: anti-
HCV positivity increased with longer lengths of injecting;
it was higher for daily injectors; and it was raised in partic-
ipants who reported having ever injected with used nee-
dles and syringes. In Belgrade, anti-HCV positivity was
also associated with being female, lower educational
attainment, less frequent use of the same syringe before
disposal, and imprisonment, whilst in Podgorica it was
associated with older age, being detained or arrested by
the police and having ever had a previous HCV test. These
results suggest an urgent need for interventions which
focus on reducing injecting risk behaviour and targeting
recent initiates to injecting prior to the point of HCV
transmission. Mathematical modelling studies suggest
that in each population of IDUs there may be a small pro-
portion which is at the greatest risk of acquiring HIV and
HCV, and that targeting these may have a large impact on
subsequent levels of infection.[35] Qualitative research in
Montenegro also emphasises an adverse relationship
between policing practices and injecting risk behav-
iour.[26] Elevated risk linked to policing and prison sug-
gests the need for hepatitis C prevention which focuses
not only on risk awareness among IDUs but on social and
institutional change.[36]
Testing
Uptake of rapid HIV testing during the study in Belgrade
was relatively high, considering it was a novel interven-
tion in this population; half of the sample wanted to
know their HIV status and had pre-test counselling. This
finding, similar to other evidence, suggests that rapid HIV
testing in community settings can effectively target large
numbers of people at high risk of HIV infection.[21]
Qualitative research in Serbia suggests reluctance among
IDUs to access state testing services, and a lack of normal-
ised routine testing for anti-HIV and anti-HCV.[9,37] This
is in a context of fears that confidentiality may be
breached, mistrust of state health services, and a culture of
non-disclosure regarding viral health status. We found
complete concordance between the results from rapid
testing and confirmatory testing, and no samples from
HIV-infected participants registered weak positive reac-
tions. Our rapid test algorithm therefore provided specifi-
city comparable to EIA/Western Blot, and good sensitivity,
albeit with broad confidence intervals due to few posi-
tives.
For this study each participant was tested contemporane-
ously by both rapid HIV POCT devices. Their accuracies
were identical, albeit on a relatively small population. For
routine use it is recommended that a single POCT device
be used to screen individuals and that a second POCT
device is held in reserve for immediate application to indi-
viduals whose initial test is reactive. Particularly in popu-
lations with a low HIV prevalence, and for which further
confirmatory testing may not be available, the use of a
third POCT device is recommended to minimise any risk
of false positive diagnoses.[38] It is important to select
POCT devices that are highly sensitive and specific, easy to
perform and whose end-point reaction is easily read. Fur-
thermore to ensure a very high positive predictive value it
is necessary to demonstrate that the second (and third)
POCT device is not prone to the same false positive reac-
tions of the first. There is very little difference in perform-
ance between quality POCT devices (see
http:www.who.int/diagnostics_laboratory/publications/
eval uations/en/index.html for further information) and
consequently the substantial additional costs of testing
every individual in parallel by two devices are not counter-
balanced by any worthwhile gain in sensitivity. Indeed,
such approaches are likely to increase the number of inde-
terminate (discordant) findings, with unnecessary uncer-
tainty for the individual and yet more expense to resolve
these discrepancies.
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Limitations
A limitation of our study was that despite some piloting of
the ACASI program, we only detected during analysis that
one of the facilities enabling participants to skip questions
was not functioning properly. This led to missing data, the
potential effects of which we have attempted to minimise
through the use of multiple imputation methods. Also, on
occasions the numbers of IDUs trying to enrol in the study
at any one time were too large to manage at the recruit-
ment sites, with the risk that not all of those invited to
return at a later appointed time actually did so. We
recorded a few instances of individuals trying to enrol
who did not meet the eligibility criteria for the study or
attempting to enrol for a second time,(LG Johnston, per-
sonal communication) which may indicate that the incen-
tive used in the study may have been too high.
Despite these limitations, we believe that the combina-
tion of community recruitment using RDS techniques,
ACASI, and rapid HIV testing, with linked diagnostic vali-
dation, is the optimal methodology for future community
surveys of IDUs. RDS provided a useful method to recruit
a large number of IDUs from community settings in a rel-
atively short space of time (six weeks in Belgrade and five
weeks in Podgorica). There was strong anecdotal support
among the survey staff that the study penetrated previ-
ously unknown social networks of IDUs. For instance,
three weeks into the study in Podgorica groups of IDUs
who were younger, more affluent and from a 'stable' area
of the city, began enrolling in the study (LG Johnston, per-
sonal communication). The use of fixed sites enables sur-
vey staff to screen potential participants for eligibility to
join the study, administer questionnaires by ACASI, and
deliver VCT to a hard-to-reach population in an informal
community setting.
Conclusion
In settings where there are multiple social and structural
barriers to gaining access to testing services,[9] rapid HIV
testing may not only provide an incentive to participate in
research but may also be considered an ethical public
health imperative, providing research participants with
low threshold access to testing services. Alongside an
urgent need to provide low threshold access to testing
services among IDUs who remain hidden or reluctant to
contact existing medical services, our findings emphasise
a general need for harm reduction interventions targeting
IDUs early in their injection careers to prevent HCV and
maintain containment of HIV. With only one needle and
syringe outlet in each of the cities of Belgrade and Podgor-
ica at the time of the study, and limited access to opioid
substitution treatment at optimum dose, a key target is the
scale-up of harm reduction services for IDUs in Serbia and
Montenegro.
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